Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia
Delveinsight
FEBRUARY 9, 2021
Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod. Breyanzi targets CD19, a protein that is highly expressed on the surface of B cells, which remain there following the transformation of these cells from normal to malignant. TG Therapeutics Wins FDA Nod for Ukoniq for Marginal Zone Lymphoma and Follicular Lymphoma.
52 
Let's personalize your content